Jonathan Z. Baskin

TL;DR: The safety and preliminary effectiveness of a second generation device, the Upper Airway Stimulation (UAS) system, is examined, and baseline predictors for therapy success are identified.

TL;DR: Long-term 3-year improvements in objective respiratory and subjective quality-of-life outcome measures are maintained and UAS is a successful and appropriate long-term treatment for individuals with moderate to severe OSA.

TL;DR: Withdrawal of therapeutic upper airway stimulation results in worsening of both objective and subjective measures of sleep and breathing, which when resumed results in sustained effect at 18 months.

TL;DR: In a selected group of patients with moderate to severe OSA and body mass index ≤ 32 kg/m2, hypoglossal cranial nerve stimulation therapy can provide significant improvement in important sleep related quality-of-life outcome measures and the effect is maintained across a 2-y follow-up period.

TL;DR: Upper airway stimulation maintained a sustained benefit on patient-reported outcomes (ESS, FOSQ, snoring) at 48 months in select patients with moderate to severe obstructive sleep apnea.